Assembly Biosciences Q3 net loss widens on increased R&D costs
ASMB•Assembly Biosciences’ third-quarter net loss widened to $20.26 million as operating expenses rose to $26.37 million and collaboration revenue fell sharply from a year earlier. The company received a $75 million extension fee from Gilead and projects its cash runway into 2029.
1. Quarterly results
Assembly Biosciences reported a third-quarter net loss of $20.26 million, or $0.93 per share. Operating expenses were $26.37 million, including higher research and development costs tied to clinical trial activity and increased general and administrative costs.
2. Revenue and outlook
The company said collaboration revenue fell mainly because the transaction price of its HSV helicase primase inhibitor license was reduced by $11.3 million, reflecting research and development costs expected to be reimbursed to Gilead. Assembly received a $75 million extension fee from Gilead and projects its cash will fund operations into 2029.
3. Planned studies
Assembly expects to begin a Phase 2 study of ABI-6250 in cholestatic liver diseases in the first quarter of 2027. Gilead is expected to start a Phase 2 study of GS-1179 for recurrent genital herpes by the end of 2026.
